RxDoctor Payments Data

Amy Althoff, MD

Infectious Disease · Philadelphia, PANPI 1972707446

Payments from drug & device makers

$17,008in general payments, 2019–2025

Across 65 payments — averaging $261.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$17K
  • Viiv Healthcare Company$136
  • Gilead$99
  • AstraZeneca$11

What the payments were for

  • Food & beverage$246100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer57$16,762
Viiv Healthcare Company2$136
Gilead5$99
AstraZeneca1$11

How this compares

$17,008 in reported general payments places this provider in the 85th percentile of 457 infectious disease providers in Pennsylvania.

See all infectious disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$19,900
Medicare patients
46
Services billed
290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala248$1,018,582
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf32$197,260
DovatoDolutegravir Sodium/Lamivudine54$159,671
TriumeqAbacavir/Dolutegravir/Lamivudi26$99,018
OzempicSemaglutide23$21,092
EliquisApixaban31$20,241
PifeltroDoravirine12$19,861
XareltoRivaroxaban12$6,695
Varenicline Tartrate15$3,629
SymbicortBudesonide/Formoterol Fumarate12$2,646
Febuxostat13$1,641
Olmesartan Medoxomil22$1,448
Novolog FlexpenInsulin Aspart11$1,391
Atorvastatin Calcium117$1,195
Eplerenone13$1,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$99$1,018,582248 claims
Viiv Healthcare CompanyDovato, Triumeq$136$258,68880 claims
PfizerEliquis$16,762$20,24131 claims
AstraZenecaSymbicort$11$2,64612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 457 infectious disease providers in Pennsylvania.

Other infectious disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →